Aquestive Therapeutics (AQST) vs Arvinas (ARVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Aquestive Therapeutics (AQST) has outperformed Arvinas (ARVN) over the past year, losing 39.5% versus a loss of 43.9%. Over five years, AQST leads with a -45.7% price change compared with -91.8% for ARVN. Aquestive Therapeutics is the larger company by market cap ($434.9 million vs $423.0 million), about 1.0 times the size, while Arvinas is growing revenue faster (-0.3% vs -22.6%).
Arvinas converts more of its revenue into profit, with a net margin of -30.8% versus -188.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AQST | ARVN |
|---|---|---|
| Share price | $3.46 | $6.46 |
| Market cap | $434.88M | $423.03M |
| 1-day change | -6.61% | -4.15% |
| YTD return | -46.44% | -45.53% |
| 1-year return | -39.51% | -43.92% |
| 5-year return | -45.68% | -91.75% |
| EPS (TTM) | $-0.65 | $-0.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $44.55M | $262.60M |
| Revenue growth (YoY) | -22.61% | -0.30% |
| Net income (latest FY) | $-83.78M | $-80.80M |
| Gross margin | 58.35% | — |
| Operating margin | -159.50% | -45.13% |
| Net margin | -188.09% | -30.77% |
| 52-week high | $6.74 | $14.51 |
| 52-week low | $2.93 | $6.33 |
| Distance from 52-week high | -48.63% | -55.48% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +169.65% | +116.72% |
| Average volume | 2.41M | 848.52K |
| Shares outstanding | 125.69M | 65.49M |
| Employees | 147 | 246 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Arvinas is more profitable, keeping -30.8 cents of every revenue dollar as net income versus -188.1 cents for Aquestive Therapeutics.
- Arvinas grew revenue faster in its latest fiscal year (-0.30% vs -22.61%).
About Aquestive Therapeutics
AQST stock →Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 147 employees
About Arvinas
ARVN stock →Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Health Care · Biotechnology: Pharmaceutical Preparations · 246 employees
AQST vs ARVN FAQ
Which is bigger, Aquestive Therapeutics or Arvinas?
Aquestive Therapeutics (AQST) is larger, with a market capitalization of $434.88M compared with $423.03M for Arvinas (ARVN).
Which stock has performed better over the past year, AQST or ARVN?
AQST returned -39.51% over the past 12 months, compared with -43.92% for ARVN (price return, excluding dividends). Past performance does not predict future results.
Are Aquestive Therapeutics and Arvinas in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.